Comment by alexanderskates

Given the cost of developing a single drug can be in the billions of dollars, what financial incentive is there for companies to spend so much on R&D and clinical development if there is no commercial exclusivity rights at the end of the pipeline? You could nationalise drug development but that is a lot of risk to burden the taxpayer with.